Results of pancreas transplantation continue to improve and up to 90% of recipients with diabetes enjoy freedom from both insulin therapy and the need for close glucose monitoring following the procedure, according to a new paper published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Pancreas transplantation is a type of surgery in which a person with diabetes receives a healthy donor pancreas while the natural pancreas is not removed. People with a successful pancreas transplant no longer need insulin and have good blood sugar control. The tradeoff is that it is a major surgical procedure and requires patients to take medications to partially suppress their immune system for the rest of their lives.
“A pancreas transplant mitigates changes in blood sugar levels, eliminates the daily stigma and burden of diabetes, restores normal blood sugar regulation in patients with complicated diabetes, and improves quality of life and life expectancy,” says Jonathan A. Fridell, MD, chief, Abdominal Transplant Surgery of the Indiana University School of Medicine in Indianapolis, Ind. “Despite steadily improving outcomes coupled with expanded patient selection criteria to include some patients with type 2 diabetes, a decline in pancreas transplant surgeries has occurred in recent years.”
Patients who have a successful pancreas transplant can achieve better glucose control beyond what can be achieved with any other form of diabetes therapy to date. However, the number of transplants has declined due to several factors, including a lack of a primary referral source and general acceptance by the diabetes care community; an absence of consensus criteria; and access, education, and resource issues within the transplant community.
“More patients with diabetes who are failing insulin therapy or experiencing progressive diabetic complications regardless of diabetes type should be considered for a pancreas transplant,” Fridell says. “All patients with diabetes and chronic kidney disease should undergo consideration for combined kidney and pancreas transplantation independent of geography or location.”
The other authors of this paper are Robert J. Stratta, MD, of Atrium Health Wake Forest Baptist in Winston-Salem, N.C., and Angelika Gruessner, PhD, of SUNY Downstate Medical Center in Brooklyn, N.Y.
The paper received no external funding.
The manuscript, “Pancreas Transplantation: Current Challenges, Considerations, and Controversies,” was published online, ahead of print.
You may also like
Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed…
Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows
Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…